(NASDAQ: KALA) Kala Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Kala Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast KALA's revenue for 2024 to be $28,164,540, with the lowest KALA revenue forecast at $28,164,540, and the highest KALA revenue forecast at $28,164,540. On average, 1 Wall Street analysts forecast KALA's revenue for 2026 to be $70,411,350, with the lowest KALA revenue forecast at $70,411,350, and the highest KALA revenue forecast at $70,411,350.
In 2028, KALA is forecast to generate $258,663,135 in revenue, with the lowest revenue forecast at $258,663,135 and the highest revenue forecast at $258,663,135.